Upstream & Downstream Processing Archives - Page 7 of 46 - BioProcess InternationalBioProcess International

Sartorius lays out $500m to buy recombinant albumin firm Albumedix

Sartorius Stedim Biotech will add a portfolio of recombinant albumin-based products used in drug manufacture and a 72,000 square-foot production facility through the acquisition of Albumedix. During its second quarter financial call last month, bioprocess vendor Sartorius spoke about its desire to acquire complementary technologies and innovation through a war chest of around €10 billion ($10.2 billion) firepower at its disposal. Less than three weeks on, and the firm has pulled the trigger, agreeing to buy Albumedix for approximately £415…

Sartorius M&A ready with €10bn war chest

by Dan Stanton

Sartorius has around €10 billion ($10.2 billion) firepower at its disposal but says it is interested in complementary technologies and innovation rather than just bulking up its market share. Like its rival bioprocess peers, Sartorius has been active in the mergers and acquisition space. The Germany-based firm has built up its product portfolio and biopharma services business through complementary M&A and is set to continue such a strategy going forward. In the firm’s first half 2022 conference call, CEO Joachim…

Danaher dismisses biotech funding crunch as it rides the late-stage wave

by Dan Stanton

Danaher is confident it will continue to see high-single to low-double digit growth within its Pall and Cytiva bioprocess businesses, despite concerns surrounding dips in biotech funding and reduced COVID-related revenue. For the second quarter 2022, Danaher Corporation reported revenues of $7.8 billion, up 9.5% on the same period last year. The company does not breakdown its results by business but during a financial call last week divulged its bioprocessing division “continued to see record activity levels” driving a combined…

Podcast: Lumen using spirulina to make ‘edible’ antibody drugs

by Dan Stanton

We sit down with Lumen Biosciences CEO Brian Finrow to discuss how his company hopes to use its spirulina-based platform to develop drugs targeting gastrointestinal disorders. Lumen Biosciences is a biotech looking to unlock the full potential of biologic drugs, whose promise has been held back by the lack of scalable technology. The firm is developing ‘oral antibodies’ using its platform based on spirulina– the protein-rich cyanobacteria touted by many health enthusiasts as a ‘superfood’ – to create tiny factories…

Podcast: Cytiva cites COVID as driver for biopharma resilience

by Dan Stanton

Emmanuel Ligner, CEO of self-described bioprocess “critical actor” Cytiva talks us through the changing biomanufacturing landscape and unveils his firm’s sustainability report in the latest BioProcess Insider Expression Platform podcast. In 2021, Cytiva launched a survey measuring industry’s confidence in the biopharma space. Focusing across five pillars – supply chain resilience, talent pool, the R&D ecosystem, manufacturing agility, and government policy and regulation – the Biopharma Resilience Index averaged an overall score of 6.6 out of 10 in 2021. Feedback from 2022’s…

MilliporeSigma to equip ex-BMS plant in strategic partnership with Lotte

by Dan Stanton

Lotte Group has named MilliporeSigma as its preferred bioprocess vendor to support its burgeoning US-based CDMO business. In May, Lotte Corporation made its first steps into the US through the acquisition of Bristol-Myers Squibb’s facility in East Syracuse, New York, bagging a manufacturing contract with the former owners as part of the deal. Now, as the Korean firm looks to set up its US-based biologics contract development and manufacturing organization (CDMO) operations, it has signed a Memorandum of Understanding (MoU)…

Invetech launches closed autologous cell therapy tech

by Dan Stanton

Invetech says its Korus technology will offer industry an autologous cell therapy system that provides an option with minimal tech transfer challenges. With the Korus system launched this week, Invetech is targeting autologous cell therapy developers, including those in the CAR-T, TIL, NK, DC therapeutics areas, who are looking to start their cell therapy manufacturing process with cleaner lymphocyte or monocyte populations – and improve their overall manufacturing yield. The closed system includes elutriation and cell wash using gentle counterflow…

BPI Europe: three minutes, three Danaher tech platforms

by Millie Nelson

Physical events are back with a bang and BioProcess Insider took to the exhibition floor to speak to Cytiva and Pall about their newest technologies. Technology launches have mostly been virtual over the past two years because of the COVID-19 pandemic. But as we return to standard procedure, Sushma Nayak Teichert, global product manager at Cytiva, Ignatius Gyepi-Garbrah, global product manager at Pall, and Edina Payer technical application scientist at Pall took us through what their technology does and the problems it aims…

MigVax taps Catalent to deliver COVID-19 vaccine orally

by Dan Stanton

MigVax has teamed with Catalent to develop its subunit COVID-19 vaccine MigVax-101 using the CDMO’s Zydis orally disintegrating tablet (ODT) technology. Israeli crowdfunded biotech MigVax has developed an oral vaccine against COVID-19 that uses a chimeric protein to generate three kinds of simultaneous immunological responses: mucosal, blood-based, and cell-mediated immunity. To overcome delivery issues, the firm has tapped contract development and manufacturing organization (CDMO) Catalent to undertake a feasibility study to formulate MigVax-101 using its Zydis Bio orally disintegrating tablet…

High cost of complex biomanufacturing ‘a problem worth solving,’ says Waters

by Dan Stanton

With the cost of manufacturing accounting for as much as 70% for cell and gene therapies, industry must look to bioprocessing efficiencies and collaboration, says Waters Corporation. Waters Corporation is an analytical instruments, software, and service company. At the firm’s 2022 investor day last week, CEO Udit Batra spoke about the difference between producing small molecules, where “you get approval to produce a product with specific chemical and physical properties,” and the present biomanufacturing landscape, where the approval is for…